I tially described as platelet proteins localized within secretory granules 24 years ago.' However, the demonstration that idiopathic thrombocytopenic purpura (ITP) was caused by anti-platelet and that thrombocytopenic patients had abnormally high concentrations of platelet-associated IgG4.6 led to an implicit assumption that platelet IgG was anti-platelet antibody. Most subsequent studies of platelet IgG focused on the potential value of IgG measurements in the diagnosis of thrombocytopenias. The normal values for platelet IgG with different methods varied enormously, from as few as 100 to as many as 40,000 molecules per latel let.'.^ Although most patients with ITP had high concentrations of platelet IgG by any method, the specificity of platelet IgG measurements seemed poor: many patients with apparently nonimmune etiologies for their thrombocytopenia also had high platelet concentrations of IgG.9.'0 Another initially puzzling observation was that platelet albumin was increased in patients with ITP, parallel to the increased platelet concentration of IgG.".l2 These observations challenged the assumption that all platelet IgG is anti-platelet antibody.
Recent data have demonstrated that almost all platelet IgG, as well as other plasma proteins, are contained within the secretory a-gran~les."-'~ A very small fraction of normal platelet IgG, less than 1% of the total, is on the cell ~u r f a c e .~~~~" In platelets from patients with ITP, as in normal platelets, IgG is essentially all secreted in response to thrombin, supporting its a-granule 10cation.I~ The origin and significance of these two platelet pools, a-granule IgG (also referred to as total platelet IgG) and surface IgG, in normal subjects and patients with thrombocytopenia, are the subjects of this review. Two questions will be addressed. From a clinical perspective, why are the platelet concentrations of both a-granule IgG and surface IgG increased in both ITP and some apparently nonimmune thrombocytopenias? From the perspective of cell biology, how do normal platelets acquire plasma proteins, such as IgG, and target them to their secretory a-granules?
CLINICAL SIGNIFICANCE OF PLATELET IGG IN PATIENTS WITH THROMBOCYTOPENIA
There have been many studies of platelet IgG in patients An underwith thrombocytopenia over the past 15 standing of the different pools of platelet IgG is essential to interpret the published data, and to appreciate the potential clinical value of these measurements. In this discussion, a-granule (total platelet) IgG and platelet surface IgG will be considered separately: their methods of measurement, their concentrations in normal platelets, and their abnormalities in patients with thrombocytopenia are distinct.
Normal platelets contain about 5 fg of IgG per platelet, equivalent to 20,000 molecules. This is approximately 200-fold the amount of IgG measurable on the surface of normal platelet^.^.' For the analyses in this review, if the value for the IgG content of normal subjects in a published report was over 5,000 molecules per platelet (50-fold the normal platelet surface amount) and if, from the description of the assay method, it seemed probable that a-granule IgG was being detected because of platelet lysis or secretion, the data are interpreted as a measure of total platelet IgG. The reasons why some earlier reports described their results as platelet surface IgG, when in fact the total platelet content of IgG was probably measured, have been previously d i s c~s s e d .~.~ Patients with ITP consistently have an increased total platelet IgG concentration'0~'6~23 (Table 1 ). In addition to the nine studies presented in Table 1 , which were selected because they also reported data on patients with nonimmune thrombocytopenia, 14 other studies have also all demonstrated an increased total platelet IgG concentration in patients with ITp4.5.1 1.12 .15.24-32 (see Table 2 in reference 8). In a prospective study, 62 of 68 patients (91%) with a clinical diagnosis of ITP had increased total platelet IgG.9 Measurements of total platelet IgG also correlated with the clinical course of ITP, returning to normal coincident with the increase in platelet count and decreasing again with recurrence of thrombo~ytopenia.~,~.~~ In many studies an inverse correlation between the total platelet IgG concentration and Total platelet (a-granule) ZgC. Data are presented from nine reports that measured total platelet IgG in patients with nonimmune thrombocytopenia in addition to patients with ITP, and in which patient characteristics were presented that allowed an assessment of the mechanism of nonimmune thrombocytopenia. In six of these studies,'6~'8~20-22 platelet lysis and/or a-granule secretion were unintentional and the original data were described as platelet surface IgG. A detailed description of the assay techniques used in these six studies and the basis for interpretating these data as total platelet IgG are presented in references 7 and 8. The diagnoses of ITP in the 265 patients reported in these studies were made by conventional clinical criteria. For this analysis, 96 patients were designated as having nonimmune thrombocytopenia due to decreased platelet production. Twenty-one of these patients were reported to have aplastic anemia. Other diagnoses included leukemia, myelodysplasia, myeloproliferative syndromes, lymphoma, carcinoma, and thrombocytopenia after massive transfusion. To avoid complex illnesses with multiple potential causes of thrombocytopenia, the only diagnosis used in this table for thrombocytopenia due to increased platelet destruction was lTP. The mean total platelet IgG for normal subjects was calculated using each report as a single value; the mean values for the patient groups were calculated for the number of individual patients reported. Data are presented as femtograms per platelet. The number of patients in each report is given in parentheses.
the platelet count in patients with ITP has been deecause it was assumed that platelet IgG was anti-platelet antibody, these correlations were interpreted to indicate that greater amounts of antibody were causing greater platelet destruction. Studies of patients with ITP have also demonstrated increased platelet concentrations of other plasma proteins: albumin, IgA, and IgM."s'2~22,32,36 Although these observations were previously difficult to explain, because it was assumed that IgG and other Igs were anti-platelet antibodies and that all plasma proteins were restricted to the platelet surface, they are consistent with the hypothesis that these plasma proteins are acquired together by fluid-phase endocytosis (see below). In ITP platelets, as in normal platelets, the a-granule concentrations of IgG, IgA, and albumin are proportional to their concentrations in p1a~ma.l~ The significant abnormality in ITP patients is that the platelet concentrations of these plasma proteins, relative to their plasma concentrations, are significantly higher than in normal subjects; ie, for any given sCr~~e~~4,S,10,1Z,16-l~,Z0,Z4,Z5,29.33-3~ B plasma concentration, ITP platelets contain more IgG, IgA, and albumin than do normal ~1atelets.I~ Why is platelet a-granule IgG increased in ITP? The hypothesis that platelet a-granule IgG is anti-platelet antibody appears to be untenable. An alternative explanation is that platelets containing more a-granule IgG (and other a-granule proteins) in patients with ITP are larger, younger platelets, containing more a-granules. In normal subjects, there is little difference in platelet volume and a-granule content between younger and older platelet^.^'.^^ However, in patients with thrombocytopenia caused by peripheral platelet destruction, the increased thrombopoietic stimulation is accompanied by a parallel increase in platelet ~o l u m e .~' .~~ In acute severe platelet destruction, large "stress" platelets, or "proplatelets," appear in the cir~ulation,~'~~' analogous to the large, polychromatophilic reticulocytes seen in acute hemolytic anemia. 49 In patients with ITP, the mean platelet volume increases sharply with more severe thrombocytopenia, and in individual patients the course of thrombocytopenia is accompanied by inverse changes in platelet volume.46 These data suggest that platelet volume is a marker for the intensity of thrombopoiesis. Because larger platelets are more d e n~e ,~' *~* ,~~ and since a-granule content is the primary determinant of platelet den~ity,~'.~' platelets in ITP would be expected to contain more a-granule proteins, such as IgG, IgA, and albumin. The reported changes in platelet volume during the course of ITP46 are remarkably equivalent to the reported changes in total platelet IgG concentration^.^*^,^' These observations suggest that the increased total platelet IgG in thrombocytopenic patients reflects increased thrombopoietic stimulation and platelet production, resulting in larger platelets containing more a-granules.
This interpretation suggests that the measurement of total platelet IgG in thrombocytopenia is analogous to the determination of the reticulocyte count in anemia. An increased total platelet content of IgG may indicate increased platelet production in response to thrombocytopenia caused by peripheral platelet destruction, just as reticulocytosis indicates increased red blood cell (RBC) production in response to hemolysis. If this hypothesis is valid, then the total platelet IgG concentration should also be increased in patients with nonimmune thrombocytopenias due to increased peripheral platelet destruction, not only in patients with ITP. Also, the measurement of total platelet IgG should distinguish thrombocytopenias caused by increased platelet destruction from thrombocytopenias caused by marrow failure. Table 1 presents total platelet IgG measurements from the nine published reports in which data were presented from patients with both ITP and nonimmune thrombocytopenias, and in which the diagnoses of individual patients with nonimmune thrombocytopenia were p r o~i d e d .~" * '~-~~ The mean normal value for total platelet IgG in these nine reports, 4.5 fg/platelet, is similar to the mean value for all 29 published reports on measurements of total platelet IgG (5.0 fg/ platelet).' Also, the mean value of 38 fg/platelet for these 265 patients with ITP is similar to the mean value of 46 fg/platelet for all 21 reports on measurements of total platelet IgG in ITP.* For personal use only. on November 15, 2017. by guest www.bloodjournal.org From Data for patients with nonimmune thrombocytopenia are difficult to analyze, because the number of patients with individually described diagnoses are few. Typically, patients with nonimmune thrombocytopenia were grouped together without distinction regarding the pathogenesis of thrombocytopenia. For the analysis in this review, patients were included in the category of thrombocytopenia due to decreased platelet production if they had a disease or condition in which marrow failure, or a t least no increased marrow response, seemed clear. The diagnoses of the 96 patients in this category included aplastic anemia, leukemia, myelodysplasia, myeloproliferative syndromes, lymphoma, carcinoma, and thrombocytopenia after massive transfusion. The total platelet IgG in these patients was essentially the same as in the normal subjects (Table 1) . Patients with myeloma and liver disease were excluded from this analysis because their plasma IgG concentration may be increased, which could cause the increased platelet a-granule IgG reported in these disorder^'^,'^.^^.^^.^^; patients with megaloblastic anemia were excluded because their larger platelets may contain more IgG.
The only diagnosis included in the category of thrombocytopenia due to increased platelet destruction for this analysis was thrombotic thrombocytopenic purpura (TTP). The clinical diagnosis and the pathogenesis of the thrombocytopenia in TTP are ~e l l -d e f i n e d~~; in other disorders, such as sepsis, the pathogenesis of thrombocytopenia may be more complex. Total platelet IgG measurements have been reported in only nine patients with TTP. In these patients, the total platelet IgG concentrations were increased, the same as in patients with ITP. An additional study of 16 patients with TTP mentioned that all had increased total platelet IgG concentrations, but no data were provided.57 In one report, the total platelet IgG content rapidly returned to normal coincident with the recovery from thrombocytopenia:' a pattern reminiscent of the responses of platelet volume and IgG content in patients with ITP discussed p r e v i o~s l y .~.~.~~.~~ Increased platelet IgG in TTP was interpreted in the original reports to indicate an unsuspected immune etiology, because platelet IgG was assumed to be anti-platelet antibody. But an alternative interpretation, that the intense thrombopoietic stimulation in TTP causes the formation and release of larger platelets with more a-granules, is more consistent with the current understanding of the pathogenesis of TTP.56
In summary, the increased concentration of total platelet IgG in patients with ITP is firmly established. If it is assumed that this measurement, which is essentially a measure of a-granule IgG, has no relevance to the presence or absence of anti-platelet antibodies, then a plausible interpretation of this observation is that increased total platelet IgG is a reflection of the presence of large, "stress" platelets produced and released during increased thrombopoietic stimulation. Consistent with this interpretation are the data presented in Table 1 , suggesting that total platelet IgG measurements are comparably increased in patients with TTP, and that they are not significantly increased in patients with thrombocytopenia not associated with increased platelet destruction. Therefore, an increased total platelet IgG content may indicate the presence of accelerated platelet production. However, the data on patients with nonimmune thrombocytopenia are sparse. This hypothesis requires further documentation and support before it can be accepted. In contrast to the normal a-granule content of 20,000 molecules of IgG per platelet, only about 100 molecules of IgG are normally present on the platelet surface (Table 2) In contrast to total platelet IgG, measurements of platelet surface IgG have not correlated with the degree of thrombocytopenia in ITP,66-68 although the amount of platelet surface IgG may inversely correlate with the severity of thrombocytopenia during the course of individual patients.6 This is comparable with the experience in autoimmune hemolytic anemia, in which greater amounts of antibody on the RBC surface do not correlate with shorter RBC survival. 69 The capability of an antibody to mediate cell damage and the importance of the antigen in cell membrane integrity are probably more critical determinants of the severity of disease. Table 2 presents data from seven studies in which platelet surface IgG was measured by platelet binding of '"I-MoAb (HB-43) or '251-staphylococcal protein A in normal subjects, in patients with ITP, and in patients with nonimmune t h r o m b o c y t~p e n i a .~~'~~'~~~~~~~~~~~~~ Platelet surface IgG was consistently increased in patients with ITP, and patients with acute untreated ITP often appeared to have higher IgG concentrations than patients with chronic refractory ITP.68 The concentration of surface IgG was also increased to a modest degree in many patients with thrombocytopenia of presumed nonimmune etiology ( 70 The data obtained with both methods in reference 10 were similar to each other and they are combined in this table.
Restriction of the analysis to these reports allows an accurate assessment of the molecules of IgG per platelet. The diagnoses of ITP were made by conventional clinical criteria. Patients were classified as acute ITP when they were studied at the time of diagnosis or within 48 hours of the initiation of treatment. Patients classified as chronic ITP were typically refractory to treatment. In two report^.^^.^^ the diagnoses of patients with nonimmune thrombocytopenia were not provided, although in reference 66, 3 of the 20 patients had TTP and their platelet surface IgG values were said to be within the normal range. In the other five reports, patients were designated for this analysis as having nonimmune thrombocytopenia due to decreased platelet production if their diagnoses were reported as aplastic anemia, leukemia, myelodysplasia, myeloma, myelofibrosis, carcinoma, or thrombocytopenia after massive transfusion. Patients were designated for this analysis as having thrombocytopenia due to increased platelet destruction if their diagnoses were reported to be TTP or hemolytic-uremic syndrome (2 1 patient^),'^.'^,^^.^^^^' disseminated intravascular coagulation (3 patients),68 or microangiopathic hemolytic anemia ( 1 patient).68 The mean platelet surface IgG for normal subjects was calculated using each report as a single value; the mean values for the patient groups were calculated for the number of individual patients reported. The number of patients in each report is given in parentheses. etiology of these disorders is generally believed to be decreased marrow production or increased platelet destruction by nonimmune mechanisms, some investigators have interpreted the presence of increased platelet IgG as indicating an immunologic contribution to the cause of thrombocytopenia.' Platelet surface IgG was usually much greater in patients with ITP than in nonimmune thrombocytopenia, but the variability among individual patients was great.' In contrast to the observations with measurements of total platelet IgG, in most studies there was no difference in the surface IgG concentrations between patients with nonimmune thrombocytopenia due to decreased platelet production or due to increased platelet destruction ( Table 2) .
The causes of increased platelet surface IgG concentrations in patients with thrombocytopenia due to an apparently nonimmune etiology are unknown. Circulating immune complexes7' may bind to platelet Fc receptors,72373 or may bind to circulating fragments of RBCs or leukocytes that are co-isolated with platelets. The platelet surface may be altered during systemic illnesses, by membrane fragmentation or by secretion,74 and these changes may expose new antigen^^^.^' that could react with naturally occurring a n t i b~d i e s .~~ A diminished platelet surface sialic acid concentration may also cause an increased nonspecific association of IgG with platelets.77 There are currently no data to support any of these possibilities.
Conclusions: The clinical significance of platelet IgG measurements. Studies of platelet IgG have provided a clear distinction between the IgG contained in platelet a-granules and the IgG on the plasma membrane surface. Because almost all platelet IgG is contained within a-grandes, measurements of total platelet IgG can be considered to reflect the a-granule IgG content. A review of the published data suggests a hypothesis that total platelet IgG is increased in patients who have thrombocytopenia due to increased platelet destruction, caused by either immune or nonimmune mechanisms, and not increased in patients who have thrombocytopenia due to marrow failure. This suggests that total platelet IgG is increased with the appearance of larger platelets, containing more a-granules, which are produced during the stress of increased thrombopoietic stimulation. Therefore, the measurement of total platelet IgG in patients with thrombocytopenia may be analogous to the reticulocyte count in the evaluation of patients with anemia. In contrast, measurement of platelet surface IgG appears to reflect the presence of anti-platelet antibodies in patients with ITP, and therefore this assay may be considered analogous to the direct Coombs test used to detect anti-RBC antibodies in autoimmune hemolytic a n e~n i a .~.~*
SIGNIFICANCE OF PLATELET a-GRANULE IGG IN UNDERSTANDING THE ORIGIN OF a-GRANULE PROTEINS
The demonstration that platelet IgG is primarily located within a-granules has important implications for our understanding of the origins of a-granule proteins. Although all platelet a-granule secretory proteins appear to be distributed and human platelet^.^' Clathrin-coated vesicles are present in platelets and megakaryocyte~,8~5"-~~ and they may provide a vehicle for the intracellular transport of endocytosed proteins. These observations are important additions to the fundamental concepts of cell biology, because the ability of cells to acquire proteins into secretory granules by endocytosis rarely has been r e p~r t e d~~.~~ and is not described in recent reviews of endocytosis and protein ~ecretion.'~-"~ Typically, secretory granule proteins originate from endogenous synthesis within the endoplasmic reticulum followed by vesicular transport through the Golgi stack^.'^-'^ Exogenous proteins acquired by receptor-mediated endocyosis enter the cell within clathrin-coated vesicles and are transported via endosomal v a c o~l e s~'~ to lysosomes, or returned to the cell surface99~'02~104~105 (Fig 1) . Fluid-phase endocytosis, also described as pinocytosis,lo6 is a very active processlo7 by which soluble materials are acquired in proportion to their concentration in the extracellular fluid.lo6 Fluid-phase endocytosis may be a passive accompaniment of receptor-mediated or may occur via distinct pathways."' Although markers for fluid-phase endocytosis are also largely delivered to lysosomes or returned to the extracellular milieu, some material may enter the Golgi c o m p l e~~~~"~~"~ from which it could be directed to secretory granules.I12
Observations on platelet IgG, IgA, and albumin suggest that they are incorporated into a-granules by fluid-phase endocytosis of whole plasma. The relative concentrations of these proteins are the same in both platelets and plasma,* both in normal subjects and in patients with a broad range of serum protein abnormalitie~."~'~,~~,~~.~~ Also, the distribution of IgG heavy chain subtypes is parallel in platelets and plasma (IgG, > IgG, > IgG, = IgG4).7,26,82383 Endocytosis and transcytosis of monomeric IgG are ~e l l -k n o w n , "~ especially for the developing fetus, which acquires antibodies by *The terms "plasma" and "serum" are used interchangeably. A previous study has documented the validity of this equivalence for measurements of Igs and albumin." receptor-mediated transcytosis of IgG across the endothelial barriers of both the placenta and fetal vessels."ss116 Platelets contain an IgG Fc receptor (FcyR) similar or identical to the FcyR-I1 of monocytes, macrophages, B lymphocytes, and placental syncytial tr~phoblasts.~~."'~''~ Wh en FcyR-I1 is expressed in epithelial cells, it can mediate polarized transport of IgG across the However, this receptormediated mechanism may be unlikely for the acquisition of a-granule IgG because the platelet FcyR-I1 receptor has a low affinity for monomeric IgG,72,73 and it binds IgG, and IgG, preferentially to IgG, and IgG4,72."9 which is distinct from the a-granule IgG subclass d i s t r i b~t i o n .~~.~~ The hypothesis that some platelet a-granule proteins may be acquired by fluid-phase endocytosis is supported by the equivalent plateletplasma ratios of other plasma proteins that are located in a-granules, but are not known to be synthesized by megakaryocytes or platelets: IgM, a,-macroglobulin, and a,-antitrypsin (group I proteins in Table 3 ). The parallel concentrations of these proteins in a-granules and plasma suggests that they are acquired by the endocytosis of whole plasma.
Different origins of the secretory proteins are suggested by the parameter of relative platelet-plasma concentrations (Table 3) . a-Granule proteins that are synthesized by megakaryocytes and platelets (group I11 in Table 3) . Thrombospondin is synthesized by megakaryocytes as well as by many other ce11s,'22*'33.'34 which may contribute to the plasma ~0ncentration.l~~ However, thrombospondin is primarily an insoluble component of the extracellular m a t r i~"~. '~~; therefore, the plasma concentration of thrombospondin is low, comparable with the plasma concentrations of platelet factor 4 and 0-thromboglobulin.
The parameter of relative platelet and plasma concentrations of a-granule proteins further suggests that fibronectin, high molecular weight (mol wt) kininogen, and fibrinogen are distinct from the proteins in groups I and 111. Fibronectin and high mol wt kininogen are not synthesized by megakaryoc y t e~, "~, '~~-"~ and their acquisition by endocytosis may be assumed. Although some studies have reported fibrinogen synthesis by megakaryocyte^,'^'-'^' other data suggest that fibrinogen is not synthesized by megakaryocytes but is acquired by e n d o c y t~s i s . ' "~'~~~'~~ The higher plate1et:plasma ratios of these proteins compared with group I proteins may reflect their affinity for specific receptors on platelets and megakaryocyte^'^^.'^^ and suggests a-granule acquisition by receptor-mediated endocytosis. Receptor-mediated endocyto- Platelet a-granule proteins were selected for presentation in this table to present a hypothesis that their relative concentrations in platelets and plasma may be related to their mechanism of acquisition by megakaryocytes or platelets. The a-granule proteins are divided among three groups, each with distinct relative concentrations in platelets and plasma. Group I proteins are not known to be synthesized by megakaryocytes and there are no known surface receptors for these proteins in megakaryocytes or platelets (other than the Fc receptors for IgG). Group II proteins also are not synthesized by megakaryocytes, but there are well-described receptors for these proteins on platelets. Group Ill proteins are all known to be synthesized by megakaryocytes. vWF, coagulation factor V, and thrombospondin are also synthesized in other tissues, therefore their relative concentrations in platelets compared with plasma may reflect the contributions of cells other than megakaryocytes and platelets to the protein concentration in plasma. The platelet concentrations of these proteins are from the following references, cited in the table: 13,15,133,147,160-168. The data in the original reports were recalculated as milligram per milliliter assuming a platelet volume of 9.6 fL;16' therefore, 1 mL of platelets = 1.04 x 10" platelets. Plasma concentrations are from the following references, cited in the table: 15,133,136,147,16 1,165,168,170-1 component of normal plasma fibrinogen that possesses additional acidic residues on the carboxy-terminus of the y-chains15'; it does not bind to the platelet G P IIb-IIIa fibrinogen r e c e p t~r "~. '~~ and is not present in cu-gran~les.'~~.'~~ In a patient heterozygous for an inherited abnormal fibrinogen, fibrinogen Paris I, only the normal fibrinogen was present within the ~1 a t e l e t s . I~~ The mutant fibrinogen Paris I has an abnormal y-chainI5' that may inhibit binding to platelet G P IIb-IIIa. The incorporation of plasma fibrinogen into circulating platelets" suggests that endocytosed fibrinogen may be transported directly to the a-granules, without the requirement for processing through the Golgi system < Fig 1. (A) Hypothetical pathways of intracellular protein traffic leading t o the secretory a-granules in the megakaryocyte. Typically, proteins destined for the regulated secretory granules are endogenously synthesized within the endoplasmic reticulum, processed during transport through the Golgi stacks, and targeted t o the secretory granules within vesicles budding from the rr8ns-Golgi network. In megakaryocytes. this is the proposed origin of u-granule proteins in group 111 in Table 3 . Megakaryocyte a-granule proteins may also be acquired by endocytosis. Protein endocytosis is typically mediated by membrane surface receptors that cluster within clathrin-coated pits; bound proteins are then enclosed within coated vesicles and transported t o endosomal vacuoles. Endosomal contents are sorted and directed in new vesicles t o lysosomes or back t o the cell surface, but some endosomal contents can reach the Golgi. In this figure, three hypothetical pathways are illustrated for the delivery of endocytosed proteins t o the a-granule: (1 I direct transport from the plasma membrane surface within a coated vesicles3: (2) transport within a coated vesicle t o an endosome, with subsequent vesicular transport from the endosome t o the a-granule; and (3) transport via an endosome and subsequently through the Golgi stacks before arriving at the a-granule. Proteins acquired by either fluid-phase endocytosis or receptor-mediated endocytosis (groups I and II in Table 3 ) may travel on the same paths. (B) Hypothetical pathways of intracellular protein traffic leading t o the secretory a-granules in the platelet. Being merely a fragment of megakaryocyte cytoplasm, the platelet contains only remnants of endoplasmic reticulum, Golgi stacks, and endogenous protein synthesis. Circulating platelets can acquire fibrinogen directly from plasma and store it within a-granulessO: this transport may proceed directly from the surface membrane t o the a-granule within a clatherin-coated ~esic1e.g~ Some endocytosed proteins may also be delivered t o lys~somes."~ as in other cells.
For personal use only. on November 15, 2017. by guest www.bloodjournal.org From (Fig 1) . GP IIb-IIIa has been shown to cycle between the cell surface and intracellular vacuole^,'^^ a process that could facilitate fibrinogen endocytosis, and to be present on the internal face of a-granule membra ne^."^ While the postulated mechanisms of protein acquisition by platelet a-granules presented in Table 1 appear feasible, there are experimental observations of a-granule acquisition by endocytosis only for IgG and albumin in guinea pig megakaryocyte^,^^ and fibrinogen in guinea pig megakaryocytes and platelets and human platelet^.*^*^^ Beyond these direct observations, the questions about the a-granule acquisition of IgG, and other plasma proteins, cannot now be answered: Can platelets, in addition to megakaryocytes, to acquire IgG? What are the pathways of intracellular transport of endocytosed plasma proteins within megakaryocytes and platelets? Is the uptake of plasma proteins into secretory granules a specialized function of megakaryocytes and platelets, or is it a more common mechanism in other cells than is currently suspected?
CONCLUSIONS
Studies on platelet IgG have provided important observations for understanding the origin of platelet a-granule proteins. It has been demonstrated that megakaryocytes can acquire a-granule IgG, as well as albumin, from plasma, and that both megakaryocytes and platelets can acquire a-granule fibrinogen from plasma. a-Granule IgG reflects the composition and concentration of plasma IgG, suggesting that it is acquired by fluid-phase endocytosis. Even though all secretory proteins appear to be distributed among all a-granules, the relative concentrations of a-granule proteins in platelets and plasma suggest that there are several distinct mechanisms of acquisition for these proteins: endogenous synthesis, receptor-mediated endocytosis, and fluid-phase endocytosis. These observations may have implications for the mechanism of acquisition of secretory proteins in other cells.
Measurements of platelet IgG can detect either total platelet IgG, representing a-granule IgG, or platelet surface IgG, which is less than 1% of the total in normal subjects. Both total platelet IgG and platelet surface IgG are increased in patients with ITP. Total platelet IgG concentrations also appear to be increased in patients with nonimmune thrombocytopenia due to increased peripheral destruction, and may distinguish these patients from patients with thrombocytopenia due to marrow failure. The increased total platelet IgG in patients with thrombocytopenia due to increased platelet destruction may reflect the larger platelets, containing more a-granules, produced under the stress of increased thrombopoietic stimulation. Therefore, the significance of an increased total platelet IgG concentration (in the presence of a normal serum IgG concentration) in a patient with thrombocytopenia may be analogous to the significance of an increased reticulocyte count in a patient with hemolytic anemia. Platelet surface IgG appears to largely represent anti-platelet antibody. However, smaller increases of platelet surface IgG may also be present in patients in whom the thrombocytopenia is generally considered to have a nonimmune etiology; the cause for this is unknown.
If the hypotheses presented in this review are supported by further study, the selective use of platelet IgG measurements may provide information on the pathogenesis of thrombocytopenia. However, at this time the diagnosis and management of thrombocytopenia remain primarily matters of clinical judgement. 
